Cambridge, MA | Oct 2026 PRNewswire/-- Clear Scientific, Inc. announced positive top-line results from its Phase 2 trial of CS-1103, a small-molecule sequestrant that immediately binds and inactivates fentanyl, subsequently accelerating its removal from the body into urine. The results provide validation of CS-1103's novel mechanism of action. The trial met all endpoints, with CS-1103 accelerating the removal of fentanyl in human subjects and showing a favorable safety profi

Cambridge, MA | August 2026 A novel drug sequestrant-based therapeutic candidate reverses methamphetamine-induced hyperthermia and hypermetabolism and abates multiorgan toxicity in rats - ScienceDirect In a preclinical study funded by the National Institute on Drug Abuse, CS-1103 protected against methamphetamine overdose, for which there are currently no medications. This pioneering work was conducted by Dr. Joe Cotten, MD, PhD and Dr. Elie Adam, PhD at Mass General Brigham

Cambridge, MA | August 2026 Clear Scientific, a clinical-stage biopharmaceutical company, was awarded a $5.2M award from the NIH’s National Institute on Drug Abuse to continue the development of CS-1103 through Phase 2 clinical trials for the reversal of methamphetamine intoxication. Illicit stimulant use, especially methamphetamine, is a major public health crisis for which there are no FDA-approved therapeutics. Clear Scientific has raised an additional $2.6M in an open SA